Sponsor or institution

Clinical trials and research at Abbisko Therapeutics Co, Ltd

• 12Clinical trials
• 3Countries

Newest trials

All recruiting trials (12)

• ABSK211 in people with KRAS-altered advanced solid tumors

  A first-in-human study tests ABSK211 in adults with KRAS-altered advanced solid tumors to see if it is safe and how it behaves in the body.

  Recruiting Phase 1 Abbisko Therapeutics Co, Ltd · Shanghai, Shanghai Municipality · NCT07718165

• How ABSK-011 behaves in the body with different meals and with an acid reducer in healthy people

  This study tests how meal fat content and omeprazole affect how ABSK-011 capsules move through the body in healthy adults.

  Recruiting Phase 1 Abbisko Therapeutics Co, Ltd · Wuxi · NCT07700953

• ABSK141 for advanced solid tumors with KRAS G12D mutation

  This trial tests an oral drug called ABSK141 to see if it is safe and helps adults with advanced solid tumors that have a KRAS G12D mutation.

  Recruiting Phase 1/2 Abbisko Therapeutics Co, Ltd · Shanghai · NCT07417189

• ABSK-011 plus supportive care versus placebo for previously treated advanced liver cancer with FGF19 overexpression

  This trial tests whether adding ABSK-011 to best supportive care helps people with advanced hepatocellular carcinoma (HCC) whose tumors overexpress FGF19 after prior systemic therapy.

  Recruiting at 49 sites Phase 2 Abbisko Therapeutics Co, Ltd · Hefei, Anhui and 50 other locations · NCT07327034

• Observing children with achondroplasia over time

  Collecting growth, clinical, and quality-of-life information from children with achondroplasia aged 2.5 to under 11 to see how the condition and treatments affect them over 6 months to 2 years.

  Recruiting at 3 sites Abbisko Therapeutics Co, Ltd · Beijing, Beijing Municipality and 7 other locations · NCT07301463

• Early testing of ABSK131 for advanced MTAP-deficient solid tumors

  This trial tests whether oral ABSK131 is safe and can shrink advanced MTAP‑deficient solid tumors in adults who have progressed on or lack standard treatments.

  Recruiting Phase 1 Abbisko Therapeutics Co, Ltd · Shanghai, Shanghai Municipality · NCT07288957

• Combination therapy with ABSK043 and Glecirasib in KRASG12C-mutated NSCLC

  This trial tests ABSK043 plus Glecirasib in adults with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer to see if this combo is safe and active.

  Recruiting at 10 sites Phase 2 Abbisko Therapeutics Co, Ltd · Hefei, Anhui and 16 other locations · NCT07164170

• Combination therapy for advanced lung cancer with specific mutations

  This study is testing a new combination of two drugs to see if they can help people with advanced lung cancer that has certain mutations feel better and live longer.

  Recruiting Phase 2 Abbisko Therapeutics Co, Ltd · Hefei, Anhui and 4 other locations · NCT06668103

• Evaluating ABSK061 and ABSK043 for treating advanced solid tumors

  This study is testing a new combination of two drugs to see if they can help people with advanced solid tumors that have specific genetic changes.

  Recruiting Phase 2 Abbisko Therapeutics Co, Ltd · Guiyang, Guizhou and 20 other locations · NCT06632262

• Evaluating Pimicotinib with Chemotherapy for Advanced Pancreatic Cancer

  This study is testing if a new drug called Pimicotinib, used with chemotherapy, can help people with advanced pancreatic cancer feel better and improve their treatment outcomes.

  Recruiting at 5 sites Phase 2 Abbisko Therapeutics Co, Ltd · Shanghai, Shanghai Municipality and 4 other locations · NCT06111274

• Assessing a new treatment for advanced liver cancer

  This study is testing a new oral treatment for advanced liver cancer to see if it is safe and effective for patients who haven't had success with other therapies.

  Recruiting at 11 sites Phase 1 Abbisko Therapeutics Co, Ltd · Phoenix, Arizona and 31 other locations · NCT04906434

• Assessing the safety and tolerability of ABSK-021 in patients with advanced solid tumors

  This study is testing a new oral medication called ABSK-021 to see if it's safe and tolerable for people with advanced solid tumors, especially those with tenosynovial giant cell tumor, who haven't had success with other treatments.

  Recruiting at 3 sites Phase 1 Abbisko Therapeutics Co, Ltd · Beverly Hills, California and 16 other locations · NCT04192344

Quick answers

How many clinical trials run by Abbisko Therapeutics Co, Ltd are recruiting right now?

12, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 3 countries. The most sites are in China (12 trials), United States (2 trials), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 5, Phase 2: 5, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →